Background: In multiple sclerosis inflammation is primarily injurious to the central nervous system, but its therapeutic suppression might inhibit repair-promoting factors.
Objectives: We aimed at better describing the complexity of biological effects during an acute relapse and analysed the effects of intervention with high-dose i.v. glucocorticoids and immunomodulatory treatment with interferon-beta (IFNβ).
Methods: We studied the intracellular expression levels of the pro-inflammatory mediators tumour necrosis factor alpha (TNFα) and inducible nitric oxide synthase (iNOS) together with the neurotrophins ciliary neurotrophic factor (CNTF) and brain-derived neurotrophic factor (BDNF) in freshly isolated peripheral blood mononuclear cells of multiple sclerosis patients during an acute relapse, after intervention with i.v. methylprednisolone and at baseline, using a highly quantitative flow-cytometric approach.
Results: We demonstrated the expression of CNTF in human leucocytes. We showed that CNTF levels differed in acutely relapsing multiple sclerosis patients compared with controls and increased after corticosteroid treatment. CNTF can counteract the toxicity of TNFα towards oligodendrocytes and we found TNFα increased during acute relapses. Following corticosteroids, neither TNFα nor iNOS expression was reduced. Levels of BDNF were not affected by glucocorticoids, but increased during IFNβ therapy. However, IFNβ also increased the expression of iNOS and major histocompatibility complex class I (MHC-I), underlining its immunomodulatory potential.
Conclusions: Multiple sclerosis patients might benefit from reparative, and not solely from anti-inflammatory, effects of glucocorticoids. Interactive effects of glucocorticoid- and IFNβ-treatment need to be considered to improve neuroprotection and remyelination resulting from immunomodulatory treatment.
BeckJRondotPCatinotLFalcoffEKirchnerHWietzerbinJ. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations?Acta Neurol Scand1988; 78: 318–323.
2.
ShariefMKHentgesR. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med1991; 325: 467–472.
3.
RieckmannPAlbrechtMKitzeBWeberTTumaniHBroocksA. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing–remitting multiple sclerosis is associated with disease activity. Ann Neurol1995; 37: 82–88.
4.
MonteynePSindicCJ. Data on cytokine mRNA expression in CSF and peripheral blood mononuclear cells from MS patients as detected by PCR. Mult Scler1998; 4: 143–146.
5.
OlssonT. Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev1995; 144: 245–268.
SelmajKWRaineCS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol1988; 23: 339–346.
10.
ZajicekJPWingMScoldingNJCompstonDA. Interactions between oligodendrocytes and microglia. A major role for complement and tumour necrosis factor in oligodendrocyte adherence and killing. Brain1992; 115: 1611–1631.
11.
D'SouzaSAlinauskasKMcCreaEGoodyerCAntelJP. Differential susceptibility of human CNS-derived cell populations to TNF-dependent and independent immune-mediated injury. J Neurosci1995; 15: 7293–7300.
12.
BagasraOMichaelsFHZhengYMBobroskiLESpitsinSVFuZF. Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci USA1995; 92: 12041–12045.
13.
De GrootCJRuulsSRTheeuwesJWDijkstraCDvan der ValkP. Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J Neuropathol Exp Neurol1997; 56: 10–20.
14.
JohnsonAWLandJMThompsonEJBolanosJPClarkJBHealesSJ. Evidence for increased nitric oxide production in multiple sclerosis. J Neurol Neurosurg Psychiatry1995; 58: 107–107.
15.
YamashitaTAndoYObayashiKUchinoMAndoM. Changes in nitrite and nitrate (NO2-/NO3-) levels in cerebrospinal fluid of patients with multiple sclerosis. J Neurol Sci1997; 153: 32–34.
16.
GiovannoniGHealesSJSilverNCO’RiordanJMillerRFLandJM. Raised serum nitrate and nitrite levels in patients with multiple sclerosis. J Neurol Sci1997; 145: 77–81.
17.
SarchielliPOrlacchioAVicinanzaFPelliccioliGPTognoloniMSaccardiC. Cytokine secretion and nitric oxide production by mononuclear cells of patients with multiple sclerosis. J Neuroimmunol1997; 80: 76–86.
18.
GoldeSChandranSBrownGCCompstonA. Different pathways for iNOS-mediated toxicity in vitro dependent on neuronal maturation and NMDA receptor expression. J Neurochem2002; 82: 269–282.
19.
RedfordEJKapoorRSmithKJ. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain1997; 120: 2149–2157.
20.
SmithKJKapoorRHallSMDaviesM. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol2001; 49: 470–476.
21.
ConfavreuxCCompstonA. The natural history of multiple sclerosis. In: CompstonAConfavreuxCLassmannHMcDonaldIMillerDNoseworthyJ (eds) McAlpine`s multiple sclerosis20064th ed. Churchill Livingstone219–219. , p. 219.
22.
MoalemGLeibowitz-AmitRYolesEMorFCohenIRSchwartzM. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med1999; 5: 49–55.
23.
HammarbergHLidmanOLundbergCEltayebSYGielenAWMuhallabS. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci2000; 20: 5283–5291.
24.
HaubenEButovskyONevoUYolesEMoalemGAgranovE. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J Neurosci2000; 20: 6421–6430.
KerschensteinerMGallmeierEBehrensLLealVVMisgeldTKlinkertWE. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?J Exp Med1999; 189: 865–870.
30.
BesserMWankR. Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol1999; 162: 6303–6306.
31.
StadelmannCKerschensteinerMMisgeldTBruckWHohlfeldRLassmannH. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?Brain2002; 125: 75–85.
32.
ZiemssenTKumpfelTKlinkertWEFNeuhausOHohlfeldR. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain2002; 125: 2381–2391.
33.
AzoulayDVachapovaVShihmanBMilerAKarniA. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol2005; 167: 215–218.
34.
AzoulayDUrshanskyNKarniA. Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. J Neuroimmunol2008; 195: 186–193.
35.
LalivePHKantengwaSBenkhouchaMJuillardCChofflonM. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients. J Neuroimmunol2008; 197: 147–151.
36.
Comini FrotaERRodriguesDHDonadiEABrumDGMacielDRKTeixeiraAL. Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse. Neurosci Lett2009; 460: 130–132.
37.
GielenAKhademiMMuhallabSOlssonTPiehlF. Increased brain-derived neurotrophic factor expression in white blood cells of relapsing–remitting multiple sclerosis patients. Scand J Immunol2003; 57: 493–497.
38.
PetereitHFLindemannHSchoppeS. Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor. Mult Scler2003; 9: 16–20.
39.
LiguoriMFeraFPatitucciAMannaICondinoFValentinoP. A longitudinal observation of brain-derived neurotrophic factor mRNA levels in patients with relapsing–remitting multiple sclerosis. Brain Res2009; 1256: 123–128.
40.
SarchielliPGrecoLStipaAFloridiAGallaiV. Brain-derived neurotrophic factor in patients with multiple sclerosis. J Neuroimmunol2002; 132: 180–188.
41.
SarchielliPZaffaroniMFloridiAGrecoLCandeliereAMattioniA. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. Mult Scler2007; 13: 313–331.
42.
AzoulayDMausner-FainbergKUrshanskyNFahoumFKarniA. Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism. J Neuroimmunol2009; 211: 114–119.
43.
DuttaRMcDonoughJChangASwamyLSiuAKiddGJ. Activation of the ciliary neurotrophic factor (CNTF) signalling pathway in cortical neurons of multiple sclerosis patients. Brain2007; 130: 2566–2576.
44.
BarresBASchmidRSendtnerMRaffMC. Multiple extracellular signals are required for long-term oligodendrocyte survival. Development1993; 118: 283–295.
45.
SendtnerMKreutzbergGWThoenenH. Ciliary neurotrophic factor prevents the degeneration of motor neurons after axotomy. Nature1990; 345: 440–441.
46.
OppenheimRPrevetteDYinQCollinsFMacDonaldJ. Control of embryonic motoneuron survival in vivo by ciliary neurotrophic factor. Science1991; 251: 1616–1618.
47.
StockliKLillienLNaher-NoeMBreitfeldGHughesRRaffM. Regional distribution, developmental changes, and cellular localization of CNTF-mRNA and protein in the rat brain. J Cell Biol1991; 115: 447–459.
48.
SleemanMAndersonKLambertPYancopoulosG. The ciliary neurotrophic factor and its receptor. Pharm Acta Helv2000; 74: 265–272.
49.
D’SouzaSDAlinauskasKAAntelJP. Ciliary neurotrophic factor selectively protects human oligodendrocytes from tumor necrosis factor-mediated injury. J Neurosci Res1996; 43: 289–298.
50.
BarresBAHartIKColesHSRBurneJFVoyvodicJTRichardsonWD. Cell death in the oligodendrocyte lineage. J Neurobiol1992; 23: 1221–1230.
51.
LouisJ-CMagalETakayamaSVaronS. CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death. Science1993; 259: 689–692.
52.
TakahashiRYokojiHMisawaHHayashiMHuHDeguchiT. A null mutation in the human CNTF gene is not causally related to neurological diseases. Nat Genet1994; 7: 79–84.
53.
HoffmannVPohlauDPrzuntekHEpplenJTHardtC. A null mutation within the ciliary neurotrophic factor(CNTF)-gene: implications for susceptibility and disease severity in patients with multiple sclerosis. Genes Immun2002; 3: 53–55.
54.
GiessRMaeurerMLinkerRGoldRWarmuth-MetzMToykaKV. Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch Neurol2002; 59: 407–409.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50:121–127.
57.
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. HYPERLINK “http://www.ncbi.nlm.nih.gov/pubmed/16283615” Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58: 840–846.
58.
MaierKRauCStorchMKSattlerMDemmerIWeissertR. Ciliary neurotrophic factor protects retinal ganglion cells from secondary cell death during acute autoimmune optic neuritis in rats. Brain Pathol2004; 14: 378–387.
59.
KuhlmannTRemingtonLCognetIBourbonniereLZehntnerSGuilhotF. Continued administration of ciliary neurotrophic factor protects mice from inflammatory pathology in experimental autoimmune encephalomyelitis. Am J Physiol2006; 169: 584–598.
60.
Schulte-HerbrüggenONassensteinCLommatzschMQuarcooDRenzHBraunA. Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J Neuroimmunol2005; 160: 204–209.
61.
LeussinkVIJungSMerschdorfUToykaKGoldR. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol2001; 58: 91–97.
62.
RansomRFVega-WarnerVSmoyerWEKleinJ. Differential proteomic analysis of proteins induced by glucocorticoids in cultured murine podocytes. Kidney Int2005; 67: 1275–1285.
63.
CaggiulaMBatocchiAPFrisulloGAngelucciFPatanellaAKSancriccaC. Neurotrophic factors and clinical recovery in relapsing–remitting multiple sclerosis. Scand J Immunol2005; 62: 176–182.
64.
SpulerSYousryTSchellerAVoltzRHollerEHartmannM. Multiple sclerosis: prospective analysis of TNF-alpha and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity. J Neuroimmunol1996; 66: 57–64.
65.
PitzalisCSharrackBGrayIALeeAHughesRA. Comparison of the effects of oral versus intravenous methylprednisolone regimens on peripheral blood T lymphocyte adhesion molecule expression, T cell subsets distribution and TNF alpha concentrations in multiple sclerosis. J Neuroimmunol1997; 74: 62–68.
66.
KahlKGKruseNToykaKVRieckmannP. Serial analysis of cytokine mRNA profiles in whole blood samples from patients with early multiple sclerosis. J Neurol Sci2002; 200: 53–55.
67.
GoldeSColesALindquistJACompstonA. Decreased iNOS synthesis mediates dexamethasone-induced protection of neurons from inflammatory injury in vitro. Eur J Neurosci2003; 18: 2527–2537.
68.
Van WinsenLMMurisDFPolmanCHDijkstraCDvan den BergTKUitdehaagBM. Sensitivity to glucocorticoids is decreased in relapsing remitting multiple sclerosis. J Clin Endocrinol Metab2005; 90: 734–740.
69.
SmithKJLassmannH. The role of nitric oxide in multiple sclerosis. Lancet Neurol2002; 1: 232–241.
70.
HamamciogluKRederAT. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult Scler2007; 13: 459–470.
71.
KlöckerNKermerPGleichmannMWellerMBährM. Both the neuronal and inducible isoforms contribute to upregulation of retinal nitric oxide synthase activity ba brain-derived neurotrophic factor. J Neurosci1999; 19: 8517–8527.
72.
LiuJZhaoMLBrosnanCFLeeSC. Expression of type II nitric oxide synthase in primary human astrocytes and microglia: role of IL-1b and IL-1 receptor antagonist. J Immunol1996; 157: 3569–3576.
73.
LeeuwenbergJFMvan DammeJJeunhommeGMAABuurmanWA. Interferonβ-1, an intermediate in the tumor necrosis factorα-induced increased MHC class I expression and an autocrine regulator of the constitutive MHC class I expression. J Exp Med1987; 166: 1180–1185.
74.
BitschASchuchardtJBunkowskiSKuhlmannTBruckW. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain2000; 123: 1174–1183.
75.
LinkerRARottEHofstetterHHHankeTToykaKVGoldR. EAE in beta-2 microglobulin-deficient mice: axonal damage is not dependent on MHC-I restricted immune responses. Neurobiol Dis2005; 19: 218–228.
76.
ZafranskayaMOschmannPEngelRWeishauptAvan NoortJMJomaaH. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis. Immunology2007; 121: 29–39.
77.
NamdarANikbinBGhabaeeMBayatiAIzadM. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing–remitting multiple sclerosis (RRMS): a preliminary study. J Neuroimmunol2010; 218: 120–124.
78.
KorporalMHaasJBalintBFritzschingBSchwarzAMoellerS. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells. Arch Neurol2008; 65: 1434–1439.
KremenchutzkyMRiceGPBaskervilleJWingerchukDMEbersGC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain2006; 129: 584–594.
81.
ConfavreuxCVukusicS. Age at disability milestones in multiple sclerosis. Brain2006; 129: 595–605.
82.
RoxburghRHSeamanSRMastermanTHensiekAESawcerSJVukusicS. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology2005; 64: 1144–1151.
83.
JonesJLAndersonJMPhuahCLFoxEJSelmajKMargolinD. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain2010; 133: 2232–2247.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
